-
ROR Related Products (98)
Related Products (98)
-
RORγ agonist 1
0 ImagesCat. No.: HY-132900CAS No.: 2260631-91-0RORγ agonist 1 is a potent and orally bioavailable RORγ agonist (EC50 = 21 nM) with antitumor activity.
-
RORγt inverse agonist 14
0 ImagesCat. No.: HY-132195CAS No.: 2672496-70-5RORγt inverse agonist 14 (8e) is a potent, orally active and selective RORγt inverse agonist (EC50 of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis.
-
ROR agonist-1
0 ImagesCat. No.: HY-128353CAS No.: 2361528-74-5ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5.
-
RORγt Inverse agonist 2
0 ImagesCat. No.: HY-111748CAS No.: 1801197-92-1RORγt Inverse agonist 2 is a selective, orally active RORγt inverse agonist with an EC50 of 119 nM.
-
FM26
0 ImagesCat. No.: HY-133128CAS No.: 2407981-35-3FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.
-
RORγt inverse agonist 26
0 ImagesCat. No.: HY-142806CAS No.: 2738333-10-1RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .
-
TAK-828F
0 ImagesCat. No.: HY-111509CAS No.: 1854901-94-2TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
-
ARN-6039
0 ImagesCat. No.: HY-115777CAS No.: 1675206-11-7ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.
-
RORγt Inverse agonist 8
0 ImagesCat. No.: HY-122737CAS No.: 2079892-79-6RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC50 of 19 nM for human RORγt-LBD.
-
RORγ antagonist 1
0 ImagesCat. No.: HY-155542CAS No.: 3049676-15-2RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells.
-
3-Oxo-5β-cholanoic acid-d4
0 ImagesCat. No.: HY-125801SSynonyms: Dehydrolithocholic acid-d4; 3-oxoLCA-d43-Oxo-5β-cholanoic acid-d4 (Dehydrolithocholic acid-d4) is the deuterium labeled 3-Oxo-5β-cholanoic acid (HY-125801). 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM).
-
RORA Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS12126RORA Human Pre-designed siRNA Set A contains three designed siRNAs for RORA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
TMP780
0 ImagesTMP780 is an inverse agonist of RORγt with an IC50 of 13 nM. RORγt is a tractable agent target for the treatment of cutaneous inflammatory disorders.
-
3-Oxo-5β-cholanoic acid (Standard)
0 ImagesSynonyms: Dehydrolithocholic acid (Standard); 3-oxoLCA (Standard)3-Oxo-5β-cholanoic acid (Standard) is the analytical standard of 3-Oxo-5β-cholanoic acid. This product is intended for research and analytical applications. 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM)[1].
-
RORγt agonist 2
0 ImagesCat. No.: HY-142937CAS No.: 2663787-92-4RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17).
-
RORγt/DHODH-IN-1
0 ImagesCat. No.: HY-142843CAS No.: 2764662-15-7RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.
